Income statement, balance sheet and cash flow statement for the last 9 fiscal years, taken from the XBRL data Innate Pharma SA files with the SEC in its annual reports.
In EUR millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
44
94
85.4
69.8
24.7
57.7
61.6
20.1
9.01
Research and development
67
69.6
62.9
49.7
47
51.7
56
52
43.6
Selling, general and administrative
17
18.1
21
19
25.5
22.4
18.3
19.7
Operating income
-40
5.15
1.58
1.08
-47.8
-57.4
-12.7
-51.6
-54
Interest expense
10.5
8.43
4.98
6.76
4
5.32
1.84
3.98
3.12
Interest income
2.5
6
11.3
4.86
6.34
4.78
6.93
6.08
7.95
Pre-tax income
-48
2.72
7.87
-0.83
-45.5
-58
-7.57
-49.5
-49.2
Income tax
0.37
-0.33
0
0
0
0
0
0
0
Income from continuing operations
7.87
-0.83
-45.5
-58
-7.57
-49.5
-49.2
Net income
-48.4
3.05
-20.8
-64
-52.8
-58.1
-7.57
-49.5
-49.2
EBITDA
-35.6
12.5
15.3
10.5
-43.3
-53
-7.58
-49.6
-52.6
EPS, basic
-0.89
0.05
-0.31
-0.81
-0.66
-0.73
-0.09
-0.61
-0.55
EPS, diluted
-0.89
0.05
-0.31
-0.81
-0.66
-0.73
-0.09
-0.61
-0.55
Balance sheet
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
99.4
152
203
137
104
84.2
70.6
66.4
28.1
Short-term investments
16.7
15.2
16
14.8
16.1
17.3
21.9
14.4
6.22
Receivables
21.4
152
18.7
21.8
18.4
38.3
55.6
4.97
12.4
Total current assets
138
320
238
173
138
140
148
85.7
46.7
Property, plant and equipment
10.7
11.3
11.7
11.7
10.2
8.54
Intangible assets
46.2
84.5
97
46.3
44.2
1.55
0.42
0
0
Total assets
255
451
401
307
267
199
175
111
62.7
Accounts payable
24.7
91.7
49.5
29.5
28.6
20.9
17
16
15
Total current liabilities
73.9
197
122
45.5
79.9
41.3
39.6
33
36.6
Total liabilities
156
284
184
151
160
145
123
102
84.4
Paid-in capital
235
300
370
372
375
380
384
391
408
Retained earnings
-104
-139
-135
Total equity
99.4
167
217
156
107
54.2
51.9
8.83
-21.7
Total liabilities and equity
255
451
401
307
267
199
175
111
62.7
Cash flow statement
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-48.4
3.05
-20.8
-64
-52.8
-58.1
-7.57
-49.5
-49.2
Depreciation and amortization
4.4
7.4
13.7
9.39
4.57
4.42
5.09
1.99
1.38
Cash from operations
-48.1
-32.5
34.9
-51.8
-58.5
-19.2
-32.6
-6.9
-52.8
Capital expenditures
-2.96
-0.87
-1.27
-0.91
-0.93
-0.54
-0.35
-0.39
-0.14
Cash from investing
-29.5
24.3
-62.1
-13.4
-0.92
1.88
20.6
9.2
7.29
Debt issued
1.74
0
13.9
1.36
28.7
0
0
0
0
Debt repaid
-1.2
-1.34
-1.98
-2.25
-2.07
-2.03
-2.36
-8.94
-8.91
Stock issued
0.11
0.04
0.05
0.5
0.2
0.4
2.93
15
Cash from financing
0.92
61.2
77.8
-1.18
26.8
-1.83
-1.97
-6.01
6.07
Exchange rate effect
0.07
-0.03
0.01
0.22
-0.48
-0.43
0.27
-0.51
1.09
Net change in cash
-76.5
52.9
50.6
-66.1
-33
-19.5
-13.6
-4.21
-38.3
Free cash flow
-51
-33.4
33.7
-52.7
-59.4
-19.7
-32.9
-7.29
-52.9
Interest paid
0.6
0.6
0.4
Income taxes paid
-13
-8.6
-6.5
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. No valuation: the share price is quoted in a different currency than the statements.
Profitability
Metric
Value
How it is calculated
Operating margin
-599.8%
Operating income / revenue.
EBITDA margin
-584.4%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-546.1%
Pre-tax income / revenue.
Net margin
-546.1%
Net income / revenue.
FCF margin
-587.4%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-585.8%
Cash from operations / revenue.
Return on assets (ROA)
-56.6%
Net income / average total assets.
R&D / revenue
484.4%
Research and development expense / revenue.
Capex / revenue
1.6%
Capital expenditures / revenue.
D&A / revenue
15.4%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-55.2%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-46.2%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-33.6%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-43.5%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-32.0%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-27.2%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.27x
Current assets / current liabilities.
Quick ratio
1.27x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.94x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
134.6%
Total liabilities / total assets.
Interest coverage
-17.3x
Operating income / interest expense.
Working capital
€10.1M
Current assets - current liabilities.
Goodwill and intangibles / assets
0.0%
(Goodwill + intangible assets) / total assets.
Efficiency
Metric
Value
How it is calculated
Asset turnover
0.10x
Revenue / average total assets.
Receivables turnover
1.04x
Revenue / average receivables.
Days sales outstanding
352 days
365 x average receivables / revenue.
Per share
Metric
Value
How it is calculated
EPS, diluted
-€0.55
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-€0.55
Net income per basic share, as reported (split-adjusted).
What was Innate Pharma SA's revenue in fiscal 2025?
Innate Pharma SA reported revenue of €9.0M for fiscal 2025, 55.2% lower than the year before.
Was Innate Pharma SA profitable in fiscal 2025?
No. It reported a net loss of €49.2M.
How much free cash flow did Innate Pharma SA generate in fiscal 2025?
Cash from operations of €52.8M minus capital expenditures of €140.0K left free cash flow of -€52.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.